Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis

Table 1 Human epidermal growth factor receptor 2 expression in the liver metastatic foci in gastric cancer patients

Parameter	Patient (n)	HER2 + patients (n)	Ratio (%)	Pvalue
Age (yr)
< 60	59	29	49.2	< 0.05
≥ 60	25	8	32
Gender
Male	66	28	42.4	> 0.05
Female	18	7	38.9
Tumor type
Intestinal	49	23	46.9	< 0.05
Diffuse	35	9	25.7

The proportion of patients with human epidermal growth factor receptor 2 (HER2) over-expression was higher in patients with gastric cancer (GC) of the intestinal-type than in those with GC of the diffuse-type.

Table 2 Clinicopathologic parameters and survival

Parameter	Patient (n)	2-yr survival (%)	Pvalue
Age (yr)			> 0.05
< 60	56	66.1
≥ 60	28	60.7
Gender			< 0.05
Male	66	78.6
Female	18	21.4
HER2 over-expression			< 0.05
Absent	49	58.3
Present	35	41.7
Lauren classification			< 0.05
Intestinal	49	58.3
Diffuse	35	41.7
Differentiation			< 0.05
High/middle	4	80
Low/null	50	63.3
Disease-free interval (n = 84)			< 0.05
≥ 12 mo	63	7
< 12 mo	19	22.6

Disease-free survival longer than 12 mo has significant association with extended overall survival in gastric cancer patients with liver metastasis. HER2: Human epidermal growth factor receptor 2.